Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.41 |
| ▸ | PDE4A | P27815 | 10/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154624 | 1.00 | ROCK2 (0.44) | ROCK2USP30PDE4BPDE4APDE4C | |
| SCHEMBL6154752 | 0.81 | GPR119 (0.44) | ROCK2USP30IRAK4 | |
| SCHEMBL6154745 | 0.81 | GPR119 (0.44) | ROCK2USP30IRAK4 | |
| SCHEMBL3624947 | 0.77 | ACHE (0.46) | ROCK2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3624945 | 0.77 | ACHE (0.46) | ROCK2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3630454 | 0.76 | KDM4E (0.41) | ROCK2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3630458 | 0.76 | KDM4E (0.41) | ROCK2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3628372 | 0.74 | ROCK2 (0.53) | ROCK2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3628370 | 0.74 | ROCK2 (0.53) | ROCK2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6154611 | 0.73 | AAK1 (0.43) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | ROCK2 2/4885USP30 4100/4885PDE4B 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.